Daily Archives: February 21, 2023


CAR T-cell treatment provides significant remission rates in clinical trials

February 21st, 2023 CAR T-Cell therapy, Treatment

Feb 2023: In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for triple-class exposed multiple myeloma. Abecma (idecabtagene vicleucel) chimeric antigen receptor (CAR) T-cell th.... Read More

Latest CAR T Cell therapy treatment

Novel treatment target for lymphoma patients who relapse after CAR-T therapy

February 21st, 2023 CAR T-Cell therapy, Lymphoma, Treatment

Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to statistics given dur.... Read More

CAR-T-Cell- therapy in India

CT103A, CAR T-cell Therapy, has been designated as an orphan drug by the FDA.

February 21st, 2023 CAR T-Cell therapy, Myeloma

Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug designation is given .... Read More

CAR T Cell therapy in Malaysia image

CAR T-cell treatment from IASO Biotherapeutics receives new FDA approval

February 21st, 2023 CAR T-Cell therapy, Myeloma

Feb 2023: IASO Biotherapeutics' investigational CAR T-cell therapy for relapsed or refractory multiple myeloma (RRMM), CT103A, has received fast track and regenerative medicine advanced therapy designations from the U.S. Food and Drug Administr.... Read More


Dostarlimab-gxly is approved by FDA for dMMR endometrial cancer

February 21st, 2023 Drugs, Endometrial cancer

Feb 2023: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given FDA approval to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed during or after a prior platinum-contai.... Read More